1 recruiting, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Relapsed or Refractory Acute Lymphoblastic Leukemia: new trials by email Literature Review of Relapsed or Refractory Acute Lymphoblastic Leukemia trials Research Report on Relapsed or Refractory Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
| Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia single dose of CNCT19 - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Juventas Cell Therapy Ltd. | 100 | 2020-12-24 | 2025-08-08 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2)
Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Cyclophosphamide (1) · fludarabine (1)
Juventas Cell Therapy Ltd. (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1)
China (2)